Shots:

• Linnaeus will conduct 6 additional P-II cohorts evaluating LNS8801 + Keytruda in several cancer indications while the companies are currently evaluating the combination in patients who had previously responded to PD-1/L1 therapy and also LNS8801 as a monothx in patients unable to tolerate PD-1/L1 therapy due to serious immune-related AEs
• The companies will further evaluate the combination in patients with selected advanced solid tumors- based on promising preliminary safety- PD- and efficacy data
• LNS8801 (PO) is a bioavailable small molecule that is a highly specific & potent agonist of the GPER and ongoing P-I/IIa study demonstrates target engagement- c-Myc oncoprotein depletion- and clinical beneficial for advanced cancer patients

  Ref: PR Newswire | Image: Merck